WBCCI: Web-based Collaborative Care Intervention Study

Sponsor
University of Pittsburgh (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02939755
Collaborator
(none)
459
7
2
81
65.6
0.8

Study Details

Study Description

Brief Summary

To test the efficacy of a web-based stepped collaborative care intervention to reduce symptoms of depression, pain, and fatigue and improve health-related quality of life (HRQL) in advanced cancer patients and to reduce stress and depression, and fewer CVD risk factors in caregivers.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Stepped collaborative care intervention
  • Behavioral: Enhanced Usual Care
N/A

Detailed Description

The investigators will enroll patients at two UPMC sites: Montefiore Hospital, an academic medical center, and Passavant Hospital, a community based hospital. Based on our sample size estimate the investigators will have at least 364 patients and caregivers with complete data at 12 months follow up.

The patient and caregiver will be randomly assigned to one of two arms (intervention versus enhanced usual care) stratified by gender and vessel invasion. Because these factors are the two most robust prognostic factors in this patient population. At 6 and 12 months after enrollment, follow-up questionnaires and blood draws will be performed for patients and caregivers.

The stepped WBCC intervention includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website. Patients randomized to the "enhanced usual care" arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.

Intervention fidelity (e.g., consistency across care coordinators) will be reduced by requiring the care coordinators to follow a 300 page manual and providing standardized training by the PI who is a clinical psychologist. Dr. Steel (PI) has received training and certification from the American Psycho-Oncology Society in the design and analysis of psycho-oncology clinical trials and intervention fidelity. The study investigators will not prescribe any medications but rather make recommendations to the patient's oncologist, PCP, psychiatrist, or pain management specialist who will be free to accept or reject the recommendations by the study team. Medication type, dosage, and adherence to medication (e.g., self-report and pharmacy refills) will be recorded for patients in the WBCC intervention and enhanced usual care arms.

Study Design

Study Type:
Interventional
Actual Enrollment :
459 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Collaborative Care Intervention for Cancer Patients and Their Family Caregivers
Study Start Date :
Dec 1, 2016
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Stepped collaborative care intervention

The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.

Behavioral: Stepped collaborative care intervention
Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
Other Names:
  • treatment
  • Active Comparator: Enhanced Usual Care

    Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.

    Behavioral: Enhanced Usual Care
    usual care from health providers
    Other Names:
  • control
  • Outcome Measures

    Primary Outcome Measures

    1. Depression [change from baseline at 6 and 12 months]

      CES-D questionnaire

    2. Pain level [change from baseline at 6 and 12 months]

      BPI

    3. Fatigue [change from baseline at 6 and 12 months]

      FACT-fatigue questionnaires

    4. Quality of life (QoL) [change from baseline at 6 and 12 months]

      FACT-G questionnaire

    Secondary Outcome Measures

    1. serum IL-6, IL-1beta, IL-8, TNF-a and IFNg (pg/ml) [change from baseline at 6 months and 12 months]

      Blood sample collection and process

    2. serum CA19-9 (u/ml) [change from baseline at 6 months and 12 months]

      Blood sample collection and process

    3. serum CEA mg/L [change from baseline at 6 months and 12 months]

      Blood sample collection and process

    4. serum AFP ng/ml [change from baseline at 6 months and 12 months]

      Blood sample collection and process

    5. Caregivers' stress [change from baseline at 6 and 12 months]

      Caregiver's Stress, PSS questionnaire

    6. Caregivers' depression [change from baseline at 6 and 12 months]

      CES-D

    7. Caregivers' quality of life [change from baseline at 6 and 12 months]

      Dyadic Adjustment Scale

    8. Caregiver's blood pressure (mmHg) [change from baseline at 6 and 12 months]

      Blood pressure readings

    9. Caregiver's BMI (kg/m^2) [change from baseline at 6 and 12 months]

      Caregiver's height and weight calculations

    10. Caregiver's serum IL-6 (pg/ml) [change from baseline at 6 and 12 months]

      Blood sample collection and process

    11. Caregiver's serum HDL and LDL (mg/dl) [change from baseline at 6 and 12 months]

      Blood sample collection and process

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 100 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    Patients:
    • biopsy and/or radiograph proven diagnosis of hepatocellular carcinoma,cholangiocarcinoma, gallbladder carcinoma or breast, ovarian, or colorectal cancer with liver metastases with a life expectancy of at least one year;

    • age >21 years;

    • no evidence of thought disorder, delusions, or active suicidal ideation is observed or reported.

    Caregivers:
    • a spouse or cohabitating intimate partner of an advanced cancer patient being evaluated at the UPMC's Liver Cancer Center and

    • age >21 years

    Exclusion Criteria:
    Patients:
    • age < 21 years,

    • lack of fluency in English,

    • evidence of thought disorder, delusions, hallucinations, or suicidal ideation.

    Caregivers:
    • lack of fluency in English; and

    • evidence of thought disorder, delusions, hallucinations, or suicidal ideation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UPMC East Monroeville Pennsylvania United States 15146
    2 The University of Pittsburgh's Medical Center Passavant Hospital Pittsburgh Pennsylvania United States 15213
    3 University of Pittsburgh Medical Center Mercy Pittsburgh Pennsylvania United States 15213
    4 University of Pittsburgh's Medical Center Montefiore Hospital Pittsburgh Pennsylvania United States 15213
    5 UPMC Presbyterian Pittsburgh Pennsylvania United States 15213
    6 UPMC St. Margaret Pittsburgh Pennsylvania United States 15215
    7 UPMC Horizen Pittsburgh Pennsylvania United States 15219

    Sponsors and Collaborators

    • University of Pittsburgh

    Investigators

    • Principal Investigator: Jennifer L. Steel, PhD, UPMC Departemnt of Surgery

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jennifer Steel, Director and Associate Professor, University of Pittsburgh
    ClinicalTrials.gov Identifier:
    NCT02939755
    Other Study ID Numbers:
    • HCC# 20-066
    First Posted:
    Oct 20, 2016
    Last Update Posted:
    Jul 26, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Keywords provided by Jennifer Steel, Director and Associate Professor, University of Pittsburgh
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 26, 2022